Michael Nevradakis, Ph.D.'s avatarThe Centers for Disease Control and Prevention (CDC) on Thursday recommended the first-ever monoclonal antibody marketed as a defense for all newborns against respiratory syncytial virus, or RSV.

Beyfortus, also known as nirsevimab, is produced by pharma giants Sanofi and AstraZeneca.

In a press release, the CDC referred to the drug as a “powerful tool” and a “new immunization.” According to the agency:

“ACIP [Advisory Committee on Immunization Practices] voted to include nirsevimab in the Vaccines for Children program, which provides recommended vaccines and immunizations at no cost to about half of the nation’s children. …